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Background: There is currently a pandemic caused by the novel 
coronavirus SARS-CoV-2. The intensity and duration of this first and 
second waves in the UK may be dependent on whether SARS-CoV-2 
transmits more effectively in the winter than the summer and the UK 
Government response is partially built upon the assumption that 
those infected will develop immunity to reinfection in the short term. 
In this paper we examine evidence for seasonality and immunity to 
laboratory-confirmed seasonal coronavirus (HCoV) from a prospective 
cohort study in England. 
Methods: In this analysis of the Flu Watch cohort, we examine 
seasonal trends for PCR-confirmed coronavirus infections (HCoV-
NL63, HCoV-OC43, and HCoV-229E) in all participants during winter 
seasons (2006-2007, 2007-2008, 2008-2009) and during the first wave 
of the 2009 H1N1 influenza pandemic (May-Sep 2009). We also 
included data from the pandemic and ‘post-pandemic’ winter seasons 
(2009-2010 and 2010-2011) to identify individuals with two confirmed 
HCoV infections and examine evidence for immunity against 
homologous reinfection. 
Results: We tested 1,104 swabs taken during respiratory illness and 
detected HCoV in 199 during the first four seasons. The rate of 
confirmed HCoV infection across all seasons was 390 (95% CI 338-448) 
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per 100,000 person-weeks; highest in the Nov-Mar 2008/9 season at 
674 (95%CI 537-835) per 100,000 person-weeks. The highest rate was 
in February at 759 (95% CI 580-975) per 100,000 person-weeks. Data 
collected during May-Sep 2009 showed there was small amounts of 
ongoing transmission, with four cases detected during this period. 
Eight participants had two confirmed infections, of which none had 
the same strain twice. 
Conclusion: Our results provide evidence that HCoV infection in 
England is most intense in winter, but that there is a small amount of 
ongoing transmission during summer periods. We found some 
evidence of immunity against homologous reinfection.
Keywords 
HCoV-NL63, HCoV-OC43, HCoV-229E, SARS-CoV-2, public health, 
epidemiology, pandemic
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Background
We write this paper during a pandemic caused by the novel 
coronavirus SARS-CoV-2. As of 30th November 2020, there were 
62,363,527 confirmed cases and 1,456,687 deaths reported1. 
In the UK, 1,629,657 confirmed cases have been reported 
and 58,448 patients who tested positive for SARS-CoV-2 
died within 28 days of a positive test2. The UK Government 
aims to reduce the spread of SARS-CoV-2 through mixture 
social distancing measures including asking people to stay at 
home and only go outside for food, health reasons or work 
where this absolutely cannot be done from home. In addition 
to social distancing measures, a national test, trace and iso-
late system is operational across the UK. The intensity and 
duration of the second wave in winter 2020/21 will be dependent 
on the effectiveness of these public health interventions, but will 
also be impacted by whether SARS-CoV-2 transmits more 
effectively in the winter than the summer. Mathematical models 
used to predict the transmission and impact of COVID-19 in the 
UK assume that the virus will produce an immune response that 
prevents reinfection in the short term3.
Existing studies from outside the UK suggest that incidence 
of human coronaviruses in temperate climates is usually highest 
during winter, but spring and summer peaks and year-round 
circulation at varying levels have also been found4–9. There is 
minimal evidence regarding immunity and risk of repeat infec-
tion, but reinfection with common strains (HCoV OC43/229E) has 
been documented10,11 and reinfection with SARS-CoV appears 
to be theoretically plausible as it has been shown that antibody 
titres appear to decline over time, with estimates for duration of 
protection up to three years12.
Flu Watch is a cohort study measuring the community incidence 
and transmission of several respiratory viruses in England13. The 
study has the advantage of identifying mild cases of respi-
ratory infection regardless of whether they lead to medical 
attendance and can therefore measure community incidence 
of infection over time and reinfection regardless of severity. 
We aimed to describe the community incidence and seasonal 
patterns of seasonal coronavirus strains, assess the frequency of 
reinfection with homologous and heterogeneous strains, and 
among participants with two confirmed HCoV infections, 
examine how likely we were to observe the number of homolo-
gous reinfections if participants had no immunity.
Methods
Study design and procedure
This study is based on analysis of data collected as part of the 
Flu Watch study, a prospective community cohort study of 
the transmission and burden of acute respiratory illness in UK 
households. The full study design and methodology has 
been described previously13. Follow-up occurred across three 
consecutive winter seasons (Nov-Mar 2006–2007, 2007–2008, 
2008–2009), the summer and winter waves of the 2009 H1N1 
influenza pandemic (May-Sep 2009, Oct-Feb 2009–2010) and 
‘post-pandemic’ winter season (Nov-Mar 2010–2011).
Demographic data were collected at the start of each season and 
in this analysis we used age, sex, geographical region, quintile of 
Index of Multiple Deprivation 2007 (a composite measure of the 
socioeconomic status of small neighbourhoods)14. Throughout 
the season, participants were contacted weekly (via telephone or 
emailed online surveys) and asked to provide reports stating 
whether anyone in the household had experienced symptoms of 
acute respiratory illness. During all days of illness, participants 
were asked to report their symptoms and whether they took 
any time off work or study. In addition, we requested that all 
participants experiencing respiratory symptoms (includ-
ing feeling feverish, headache, having muscle aches, cough, 
sore throat, runny nose, blocked nose, and sneezing) provide 
self-administered nasal swabs on the second day of illness. 
In the first season, participants received swabs via the post 
only when they reported illness (so swabs are likely to have 
arrived later than day two of illness) and swabbing began in late 
December 2006. In all subsequent seasons, participants received 
swabs at the beginning of follow up and we requested swabs 
for all illnesses regardless of when they occurred during fol-
low up. Full details of sample handling and testing are provided 
elsewhere13,15. All swabs were tested for HCoV during the first 
four seasons, but only selected swabs were tested for HCoV 
in the pandemic and post-pandemic winter seasons. Table 1 
summarises respiratory virus PCR testing across Flu Watch 
seasons.
We have published the full dataset used in this study (see 
underlying data).
Participants
Participants were randomly selected from participating gen-
eral practice lists in England. All household members of 
each participant were invited. Households were recruited 
before each winter season. From 2008–2009, households that 
had previously participated were also re-invited to the study. 
Participants were eligible if all household members agreed to 
participate for the full season and adult household members 
(aged 16 years and older) agreed to provide blood samples for 
influenza-related research. Participants were not eligible if their 
household was larger than 6 people, if any household member 
suffered from terminal or severe illness or incapacity, or had 
heavy concurrent involvement in other research.
Outcomes
The primary outcome of interest in this study was 
PCR-confirmed coronavirus infection in participants. Three 
coronavirus strains were tested: HCoV-NL63, HCoV-OC43, and 
HCoV-229E.
Statistical analysis
We calculated the rate of PCR-confirmed coronavirus infection 
per 100,000 person-weeks. Follow-up began at the start of 
          Amendments from Version 1
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HCoV** ✓ ✓ ✓ ✓ partial partial
Influenza A (H1N1) ✓ ✓ ✓ ✓ ✓ ✓
Influenza A (H3N2) ✓ ✓ ✓ ✓ ✓ ✓
Influenza A 
(H1N1pdm09) n/a n/a n/a
✓ ✓ ✓
Influenza B ✓ ✓ ✓ ✓ ✓ ✓
RSV*** ✓ ✓ ✓ ✓ ✓ ✓
hMPV**** ✓ ✓ ✓ ✓ ✓ ✓
Adenovirus ✓ ✓ ✓ ✓ partial partal
Parainfluenza virus ✓ ✓ ✓ ✓ partial partial
Rhinovirus ✓ ✓ ✓ ✓ partial partial
*Polymerase chain reaction **Human Coronavirus ***Respiratory syncytial virus ****Human metapneumovirus
each season and ended at the earliest of the final report of 
symptoms or the end of the season. We stratified rates by 
participants’ age, sex, geographical region, quintile of Index of 
Multiple Deprivation 200714, and study season. We used a 
mixed poisson model to estimate rate ratios for confirmed 
HCoV. The dependent variable was the count of HCoV infec-
tions per season, the independent variables were participant 
characteristics at the start of each season plus an offset for 
the duration of follow-up, and the model was clustered by 
individual and household. For these descriptive analyses, we 
excluded the pandemic and post-pandemic winter seasons 
(2009–2010 and 2010–2011) as not all samples were tested for 
HCoV during these two seasons.
We used HCoV strains in participants with repeat infections to 
test the evidence for homologous immunity after infection. 
We started from a ‘null’ hypothesis of no immunity, and 
assumed that in this scenario the distribution of strains among 
participants with a second infection would be the same as 
in the entire cohort. If there is at least some immunity, we expected 
to see a pattern in which participants with a previous infec-
tion were less likely to have the same strain twice. For the eight 
participants with repeat infections, we created 100,000 simu-
lations in which strain of the second infection (HCoV-NL63, 
HCoV-OC43, or HCoV-229E) was sampled with the probabili-
ties observed in the entire cohort, and counted the number of 
homologous reinfections (zero to eight). We interpreted the 
proportion of simulations with as many or fewer homologous 
reinfections than in the observed data as evidence of immunity. In 
other words, the analysis attempts to examine the following ques-
tion “is it likely that participants would have got more homologous 
reinfections if infection provided no immunity?” Figure S1 
(extended data16 shows the first ten simulations and provides 
further detail of this method. For this analysis, we included 
data from the final two winter seasons (2009–2010 and 
2010–2011).
We also estimated the percent of illnesses that were swabbed 
and tested for the relevant seasonal panel of viruses (see 
Table S1 extended data16) as well as for HCoV by season to aid 
interpretation of results. 
Analysis was conducted using R version 3.6.2.
Ethics and consent
The ethical protocol for Flu Watch was approved by the 
Oxford MultiCentre Research Ethics Committee. (06/Q1604/103). 
Participants gave written informed consent (proxy consent for 
children).
Results
Approximately 10% of invited households agreed to participate 
in Flu Watch. Compared to the national population, the study 
population underrepresented young adults; people living in 
socially deprived areas, north England, west Midlands, and 
London; and people of non-white ethnic origin. We included 
51,002 person-weeks of follow-up and 2,907 person-seasons in the 
first four seasons. 
A total of 1,104 swabbed illnesses were tested for HCoV and 
199 cases were confirmed in the first four seasons. This total 
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excludes six HCoV positive swabs (three in winter 2008–2009 
and three in winter 2009–2010) as they were submitted 
without a participant ID. The percent of illnesses that were 
swabbed varied by season with lower adherence during Nov 
2007 – Mar 2008 and May 2009 – Sept 2010 (61.5% and 
57.0% respectively) and better adherence in the other seasons 
ranging from 83.6%–96.9% (see extended data 2 table S1). 
In the last two seasons when there was only partial testing 
(Oct 2009 – Feb 2010 and Nov 2010 – Mar 2011) the per-
cent of illnesses swabbed and tested for HCoV was 14.0% and 
24.5% respectively, which is why we did not report HCoV rates 
for these seasons. 
We calculated an HCoV incidence rate of 390 per 100,000 
person-weeks (95% CI 338–448) across the first four seasons. 
The maximum rate of HCoV was found in the 0–4 age 
group, with rate ratios lower in the 5–15; 45–64 and 65+ age 
groups compared to the 0–4 age group. Rates were similar in 
males and females, by geographical region, and by level of 
deprivation. Rates and rate ratios for participant characteristics 
are shown in Table 2.
Rates were higher in winter seasons than in the summer season 
of May-Sep 2009, during which four cases of HCoV were 
detected. Combining data across the first four seasons showed 
rates were highest in the month of February (759; 95%CI 
580–975). Considering all respiratory viruses tested for, HCoV 
and influenza both peaked in winter and then declined, whereas 
hMPV, adenovirus, RSV, and rhinovirus showed no obvious 
winter peak, though this may relate to the small number of 
cases we detected (Figure 1).
Of 216 participants with a first confirmed HCoV infection 
during any of the six seasons, eight had a second confirmed 
HCoV infection (all eight were from different households). 
These participants are shown in Table 3. None of the eight par-
ticipants had the same strain twice. No participants had a third 
confirmed HCoV infection. Based on simulations assuming no 
immunity, the probability of zero homologous reinfections in 
these eight participants was 3.48%, suggesting some evidence 
for immunity (Figure S2 extended data16).
Discussion
Our study shows that HCoV appears to follow a seasonal 
pattern in England, with peaks occurring during winter seasons 
and broadly at the same time as influenza. We collected data 
during one summer season that coincided with the start of the 
2009 H1N1 influenza pandemic, and during this period we 
found a small amount of ongoing HCoV transmission. Our 
results provide some evidence of immunity against homologous 
reinfection.
Our results support existing evidence for seasonality of HCoV 
in England with reduced transmission during summer months. 
To our knowledge, this is the first published study of HCoV 
seasonality in England and the first to show continued transmis-
sion during summer months. A 2010 review9 of HCoV-NL63 
found that it broadly followed a winter seasonal distribution in 
temperate climates (Belgium, Canada, France, Germany, Italy, 
Switzerland) with greater variation in tropical climates with 
China (Hong Kong) showing a spring and summer distribu-
tion (one study) and peaks in autumn in Thailand and October 
in Taiwan. Two further studies have been published since this 
review. The first was a community surveillance study in Utah, 
USA, which showed a broadly winter seasonal pattern8. Another 
study of swab specimens from adults and children with fever 
and acute upper respiratory infection symptoms in Guangzhou, 
China, found transmission throughout the year with a peak in 
February7.
Limited data exist on the immunising effect of previous 
infection with HCoV. Our data provide additional support for 
the immunising effect of infection in the short to medium term, 
but reinfection has been documented elsewhere. Our results 
should be interpreted with caution due to our sample size and 
the fact that we have not accounted for seasonal variations in 
strains, but it should also considered in the context of existing 
literature on immunity to HCoV, including community surveil-
lance and experimental reinfection challenge studies. In a 1971 
study of 937 medical students, reinfection with HCoV-229E 
was detected and infection with other respiratory viruses did 
not stimulate significant complement factor or neutralising 
antibody titre rises against HCoV-229E10. A combined pae-
diatric hospital inpatient and household community surveil-
lance study conducted in Kenya found second infections with 
HCoV-NL63 (20.9%), HCoV-OC43 (5.7%), and HCoV-229E 
(4.0%) over the six years of the study. This study provided evi-
dence to rule out genotype switching as a possible mechanism for 
reinfection. Two studies have also demonstrated experimental 
HCoV reinfection in humans17,18. At the time of writing, one 
animal study has been conducted to examine the possibility of 
SARS-CoV-2 reinfection19. In this study, four 3- to 5-year old 
rhesus macaques were inoculated with SARS-CoV-2 and after 
the disappearance of symptoms, two were rechallenged and no 
viral load was detected. This study is important as it provides 
the only data we currently have on SARS-CoV-2, but it should 
also be interpreted with caution due to the fact that it is a 
primate study with a small sample size.
There are several additional limitations to our analysis and 
data. Our PCR data are reliant on participants sampling when 
symptomatic, which means that we will have not detected 
asymptomatic infection leading to underascertainment of such 
cases and as a result our estimates of rates will underestimate 
the true community burden. It is likely that we also received 
fewer samples from those who were minimally symptomatic. 
Our results therefore represent minimal burden estimates and 
we were unable to examine this further as we have no paired 
serological data on HCoV, although stored residual sera are 
available for this cohort and could be examined in future. 
Additionally, we were not able to calculate rates of confirmed 
HCoV infection in the final two winter seasons because not 
all swabs were tested for HCoV. Participants were advised to 
collect samples on day two of symptoms as Flu Watch was 
primarily set up to examine influenza and we are uncertain 
whether or not this is the optimum day for sampling those 
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Table 2. Baseline characteristics of study participants and HCoV PCR+ illness rates across the first four seasons (Nov-Mar 
2006/7; Nov-Mar 2007/8; Nov-Mar 2008/9; May-Sep 2009).














Total 1,847 (100.0%) 2,907 51,002 199 390 (338-448)
Age group 0–4 111 (5.8%) 153 2,530 18 711 (422-1,124) 1 1
5–15 272 (14.3%) 405 7,021 27 385 (253-560) 0.51 (0.27-0.96) 0.50 (0.26-0.94)
16–44 537 (28.2%) 773 13,180 60 455 (347-586) 0.69 (0.39-1.20) 0.67 (0.38-1.17)
45–64 650 (34.1%) 1,035 18,487 65 352 (271-448) 0.53 (0.30-0.94) 0.55 (0.31-0.97)
65+ 337 (17.7%) 541 9,784 29 296 (199-426) 0.45 (0.23-0.86) 0.48 (0.25-0.91)
Sex Female 973 (52.7%) 1,543 26,986 105 389 (318-471) 1 1
Male 874 (47.3%) 1,364 24,016 94 391 (316-479) 1.01 (0.76-1.34) 1.01 (0.76-1.34)
Region East & East Midlands 318 (17.1%) 484 8,573 29 338 (227-486) 1 1
London 116 (6.2%) 159 2,564 11 429 (214-768) 1.44 (0.65-3.18) 1.24 (0.56-2.76)
North 273 (14.7%) 394 6,898 26 377 (246-552) 1.16 (0.63-2.14) 1.14 (0.61-2.12)
South East 297 (16.0%) 479 8,179 22 269 (169-407) 0.85 (0.45-1.58) 0.83 (0.44-1.57)
South West 698 (37.5%) 1,154 20,545 92 448 (361-549) 1.33 (0.82-2.17) 1.49 (0.91-2.44)
West Midlands 159 (8.5%) 237 4,243 19 448 (270-699) 1.42 (0.73-2.78) 1.32 (0.67-2.59)
IMD*** 
2007 1 - most deprived 99 (4.6%) 136 2,453 14 571 (312-958) 1 1
2 284 (13.3%) 366 6,499 30 462 (311-659) 0.83 (0.38-1.81) 0.89 (0.41-1.95)
3 534 (25.0%) 804 14,229 62 436 (334-559) 0.76 (0.37-1.55) 0.74 (0.36-1.53)
4 513 (24.1%) 730 12,924 46 356 (261-475) 0.64 (0.31-1.33) 0.69 (0.33-1.44)
5 - least deprived 409 (19.2%) 578 9,971 44 441 (321-592) 0.83 (0.39-1.73) 1.03 (0.49-2.16)
Missing 293 (13.7%) 293 4,926 3 61 (13-178) 0.09 (0.02-0.33) 1.76 (0.30-10.21)
Season Nov-Mar 2006/7 602 (20.7%) 602 10,751 42 391 (282-528) 1 1
Nov-Mar 2007/8 779 (26.8%) 779 14,183 70 494 (385-624) 1.30 (0.85-1.99) 1.31 (0.85-2.02)
Nov-Mar 2008/9 729 (25.1%) 729 12,315 83 674 (537-835) 1.68 (1.12-2.53) 1.68 (1.12-2.53)
May-Sep 2009 797 (27.4%) 797 13,753 4 29 (8-74) 0.07 (0.03-0.21) 0.05 (0.01-0.21)
Month Jan 1,737 (15.4%) 2,023 8,534 61 715 (547-918)
Feb 1,740 (15.5%) 2,033 8,040 61 759 (580-975)
Mar 1,722 (15.3%) 2,007 9,241 13 141 (75-241)
      May**** 681 (6.0%) 681 2,643 0 0 (0-140)
     Jun **** 679 (6.0%) 679 3,346 3 90 (18-262)
   Jul **** 649 (5.8%) 649 2,514 0 0 (0-147)
Aug 602 (5.3%) 602 2,941 0 0 (0-125)
Sep 670 (6.0%) 670 2,309 1 43 (1-241)
Nov 1,114 (9.9%) 1,280 3,050 4 131 (36-336)
Dec 1,666 (14.8%) 1,942 8,384 56 668 (505-867)
* Human Coronavirus ** Polymerase chain reaction *** Index of Multiple Deprivation ****rates for May-Sep are based on data from 2009 alone
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Figure 1. Weekly rates of PCR-confirmed viral respiratory diseases. PCR= Polymerase chain reaction, RSV = Respiratory syncytial 
virus.











1 04-Feb-08 229E 19-Jan-09 NL63 50
2 24-Nov-08 NL63 21-Dec-09 229E 56
3 01-Dec-08 OC43 16-Mar-09 229E 15
4 15-Dec-08 OC43 02-Feb-09 NL63 7
5 22-Dec-08 NL63 09-Feb-09 OC43 7
6 22-Dec-08 OC43 09-Feb-09 NL63 7
7 12-Jan-09 NL63 22-Jun-09 229E 23
8 16-Feb-09 229E 21-Dec-09 OC43 44
with HCoV. We only have one year of data collection during 
summer, during which time adherence to swabbing was lower 
than winter periods. Our ability to confidently estimate the 
levels of transmission during the summer is limited as a result 
of this, as is our description of seasonality, although as we 
have discussed earlier, these results are consistent with the 
wider literature for HCoV transmission in temperate climates. 
A conclusive picture about the seasonal pattern of SARS-CoV-2 
will require monitoring over several years to confirm. The 
generalisability of our results to SARS-CoV-2 has uncertain-
ties, but given the lack of data on this novel virus, we believe 
that these data can help inform the public health response. At this 
stage in the pandemic, it appears to be the case that the clinical 
features of mild cases of SARS-CoV-2 are similar to NL63, 
OC43 and 229E, but the likelihood of developing severe 
disease or dying is much higher although considerably less than 
in SARS-CoV and MERS-CoV20,21. Finally, because of small 
numbers in sub-groups it has not been possible to stratify 
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our results socio-economic status or ethnicity despite the fact 
that they are increasingly recognised as important factors 
associated with COVID-19 outcomes.
In summary, our data provide additional support for a winter 
seasonal pattern of HCoV in the UK and that infection has an 
immunising effect against subsequent reinfection in the short 
to medium term. For COVID-19, in the context of intensive 
control measures it may prove difficult to assess the extent to 
which virus transmission is impeded by summer conditions. 
Comparing transmission the patterns in northern and southern 
hemispheres (where seasons are reversed) will be of help in 
providing early data on this. We also need further research to 
assess the strength and duration of immune protection following 
COVID-19 exposure. Whilst our results can help inform the 
response and modelling to SARS-CoV-2 in the UK, there 
are important research questions that need answering from 
community surveillance studies that are relevant to the policy 
and public health response. We urgently need to know the true 
extent of community transmission, including estimates of the 
asymptomatic fraction of SARS-CoV-2, the symptomatology 
in community cases and case hospitalisation rates in confirmed 
cases and how this varies over time and season. Additionally, we 
need to know what the duration of viral shedding is and 




UCL Discovery: Dataset: Seasonality and immunity to 
laboratory-confirmed seasonal coronaviruses (HCoV-NL63, 
HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort 
study. https://doi.org/10.14324/000.ds.1009390916
This project contains the following underlying data:
-   Aldridge_cov_seasonality_immunity_public_data_23_
march_2020.csv (Flu Watch HCoV data)
Extended data
UCL Discovery: Dataset: Seasonality and immunity to 
laboratory-confirmed seasonal coronaviruses (HCoV-NL63, 
HCoV-OC43, and HCoV-229E): results from the Flu Watch 
cohort study. https://doi.org/10.14324/000.ds.1009390916
This project contains the following extended data:
-     Aldridge_cov_seasonality_immunity_public_code_revised.
R (Analysis replication code)
-     Aldridge_Extended data 1.pdf (Pdf file containing 
Table S1 and Figure S1 and S2)
o     Table S1. Illnesses swabbed and tested for HCoV by 
season
o     Figure S1: First ten simulations to evaluate 
evidence of homologous immunity
o     Figure S2: Probability of number of homologous 
reinfections in 8 participants, with the assumption of 
no immunity
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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David J. Muscatello   
School of Public Health and Community Medicine, University of New South Wales, Sydney, 
Australia 
In the context of the emerging COVID-19 pandemic, this article attempts to address two important 
questions - seasonality of human coronavirus infections in a temperate setting in the UK and the 
probability of re-infection by the same coronavirus in the time frame of a few years. 
 
A positive of the FluWatch study is that it examined infection incidence in a more-or-less 
representative sample of the population. This is a very rare occurrence in infection incidence study 
designs. 
 
The main limitation of the study is the limited number of non-winter seasons included - only one. A 
second limitation is that re-infection may have occurred during the periods during which follow-up 
did not occur - that is, the other missing summer seasons. 
 
I have a few minor concerns:
spelling of influenza should be lower case throughout - it is not a proper noun. 
 
○
Human Metapneumovirus should be spelled with a lower case m for the same reason - see 
footnote of Table 1. 
 
○
Abstract - I would prefer to see "100,000 person weeks" included next to all of the rate 
statistics in the result section. The highest rate is in February - should be clear that the 
highest average monthly rate was in Feb because I assume this was an average for Feb over 
the three seasons that included Feb. 
 
○
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Would be helpful if methods included the specific respiratory symptoms that triggered 
follow-up from the original study. 
 
○
Simulation description in methods could be explained better here and in the supplement. If 
I understand correctly, the aim was to compare the observed number of second 
homologous infections with the predicted number of second homologous infections. The 
predicted number was determined from 100,000 simulations that assumed that occurrence 
of a second homologous infection followed a distribution based on a null hypothesis that 
the probability of a second homologous infection was the same as the probability of the 
homologous strain occurring among all participants throughout the study period included. 
This simulation approach assumed that there was no residual immunity from a first 
infection. Thus, if the occurrence of the second homologous infection had a lower incidence 
than predicted then we might conclude that there is immunity to a second homologous 
infection. It's also not really clear why simulation was necessary when the simulation simply 
reproduces the distribution of infections observed in the study. 
 
○
The statement "The maximum rate of HCoV according to age was bimodal, peaking at ages 
0–4 and ages 16–44" seems a bit of a stretch. All other age groups apart from 16-44 were 




The results for monthly incidence are misleading e.g. in Table 2. May-Sep results are based 
on one season only. Remaining months based on three seasons. Are remaining months 
averages over 3 seasons? A footnote to the table could explain these issues. 
 
○
The authors have done well in stating that their results should be interpreted with caution. 
They could state more clearly that one important reason for this is that the summer results 
are based on one season only, and that's really insufficient to draw conclusions about 
seasonality which requires monitoring over several years to determine a seasonal pattern.
○
 
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
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Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Epidemiology, influenza, time series analysis, infectious diseases.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 30 Nov 2020
Robert Aldridge, UCL, London, UK 
Thanks very much for this helpful review - we appreciate the time you have taken to 
carefully read and provide constructive feedback on the article. We have tried to address all 
the points you have raised and below we include your comments alongside in our 
responses in bold italics. We have numbered each of our responses in order that we can 
cross-reference them across all of the reviews to this article.  
 
Reviewer comment 4:  
 
Spelling of influenza should be lower case throughout - it is not a proper noun. 
 
Author response 4:  
 
We have changed influenza to lower case throughout.  
 
Reviewer comment 5:  
  
Human Metapneumovirus should be spelled with a lower case for the same reason - see 
footnote of Table 1. 
 
Author response 5:  
 
We have changed Human Metapneumovirus in Table 1 footnote.  
 
Reviewer comment 6:  
  
Abstract - I would prefer to see "100,000 person weeks" included next to all of the rate 
statistics in the result section. The highest rate is in February - should be clear that the 
highest average monthly rate was in Feb because I assume this was an average for Feb over 
the three seasons that included Feb. 
 
Author response 6:  
 
We have added per 100,000 person-weeks to all rates in the abstract. The rate for the 
month Feb is not an average but is a rate calculated across all seasons using all cases in Feb 
as the numerator and person time at risk during Feb as the denominator. 
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Reviewer comment 7:  
  
Background 2nd paragraph - could also reference this study[ref-1]. 
 
Author response 7:  
 
[ref-1] did not appear to come through in the peer review response.  
 
Reviewer comment 8:  
 
Would be helpful if methods included the specific respiratory symptoms that triggered 
follow-up from the original study. 
 
Author response 8:  
 
We have added the following text to the methods section: 
“In addition, we requested that all participants experiencing respiratory symptoms 
(including feeling feverish, headache, having muscle aches, cough, sore throat, runny nose, 
blocked nose, and sneezing) provide self-administered nasal swabs on the second day of 
illness.” 
 
Reviewer comment 9:  
  
Simulation description in methods could be explained better here and in the supplement. If 
I understand correctly, the aim was to compare the observed number of second 
homologous infections with the predicted number of second homologous infections. The 
predicted number was determined from 100,000 simulations that assumed that occurrence 
of a second homologous infection followed a distribution based on a null hypothesis that 
the probability of a second homologous infection was the same as the probability of the 
homologous strain occurring among all participants throughout the study period included. 
This simulation approach assumed that there was no residual immunity from a first 
infection. Thus, if the occurrence of the second homologous infection had a lower incidence 
than predicted then we might conclude that there is immunity to a second homologous 
infection. It's also not really clear why simulation was necessary when the simulation simply 
reproduces the distribution of infections observed in the study. 
 
Author response 9:  
 
In response to this comment, we have reviewed and edited our description of our approach 
to this part of the analysis in the methods section, to hopefully clarify our intention with this 
analysis: 
“We used HCoV strains in participants with repeat infections to test the evidence for 
homologous immunity after infection. We started from a ‘null’ hypothesis of no immunity, 
and assumed that in this scenario the distribution of strains among participants with a 
second infection would be the same as in the entire cohort. If there is at least some 
immunity, we expected to see a pattern in which participants with a previous infection were 
less likely to have the same strain twice. For the eight participants with repeat infections, we 
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created 100,000 simulations in which strain of the second infection (HCoV-NL63, HCoV-
OC43, or HCoV-229E) was sampled with the probabilities observed in the entire cohort, and 
counted the number of homologous reinfections (zero to eight). We interpreted the 
proportion of simulations with as many or fewer homologous reinfections than in the 
observed data as evidence of immunity. In other words, the analysis attempts to examine 
the following question “is it likely that participants would have got more homologous 
reinfections if infection provided no immunity?”  Figure S1 (extended data16) shows the first 
ten simulations and provides further detail of this method. For this analysis, we included 
data from the final two winter seasons (2009–2010 and 2010–2011).” 
 
Reviewer comment 10:  
  
The statement "The maximum rate of HCoV according to age was bimodal, peaking at ages 
0–4 and ages 16–44" seems a bit of a stretch. All other age groups apart from 16-44 were 
lower than 0-4 based on adjusted RR, but 16-44 was not that much higher than all non-0-4 
age groups. 
  
Author response 10: 
 
We explored this issue further as per Author response 2 to Reviewer 1, but do not feel 
additional analysis is possible. As a result we have edited our description of these results in 
response to this reviewer comment 10 to: 
 
“The maximum rate of HCoV was found in the 0–4 age group, with rate ratios lower in the 5-
15; 45-64 and 65+ age groups compared to the 0–4 age group.” 
 
Reviewer comment 11:  
 
The results for monthly incidence are misleading e.g. in Table 2. May-Sep results are based 
on one season only. Remaining months based on three seasons. Are remaining months 
averages over 3 seasons? A footnote to the table could explain these issues. 
 
Author response 11:  
 
In Table 2 we have calculated the rate of HCoV PCR+ cases per 100,000 person-weeks. For 
each month we calculate this rate using the numerator as HCoV PCR+ cases and the 
denominator of Person-weeks across the whole month. The numerator and denominator 
for each month are each presented in Table 2 with the columns labelled, and the rate is 
specified as HCoV PCR**+/100,000 person-weeks 
(95% CI) in the column header. It is correct that May-Sep results are based on one season 
only and remaining months based on all seasons.  
In the discussion we previously noted that “We only have one year of data collection during 
summer, during which time adherence to swabbing was lower than winter periods. Our 
ability to confidently estimate the levels of transmission during the summer is limited as a 
result of this, as is our description of seasonality, although as we have discussed earlier, 
these results are consistent with the wider literature for HCoV transmission in temperate 
climates.” 
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In response to this reviewer comment 11 we have now added a footnote to Table 2 stating 
that: “****rates for May-Sep are based on data from 2009 alone”. 
 
Reviewer comment 12:  
  
The authors have done well in stating that their results should be interpreted with caution. 
They could state more clearly that one important reason for this is that the summer results 
are based on one season only, and that's really insufficient to draw conclusions about 
seasonality which requires monitoring over several years to determine a seasonal pattern. 
 
Author response 12:  
 
In addition to the following text in the discussion:  
“We only have one year of data collection during summer, during which time adherence to 
swabbing was lower than winter periods. Our ability to confidently estimate the levels of 
transmission during the summer is limited as a result of this, as is our description of 
seasonality, although as we have discussed earlier, these results are consistent with the 
wider literature for HCoV transmission in temperate climates.” 
We have added the following text in response to this point: 
“A conclusive picture about the seasonal pattern of SARS-CoV-2 will require monitoring over 
several years to confirm.”  
Competing Interests: No competing interests were disclosed.
Reviewer Report 06 May 2020
https://doi.org/10.21956/wellcomeopenres.17340.r38640
© 2020 Wingfield T. This is an open access peer review report distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Tom Wingfield   
Departments of Clinical Sciences and International Public Health, Liverpool School of Tropical 
Medicine, Liverpool, UK 
This is a well-written and executed article by a team that is well experienced in the field and have a 
strong track record. 
 
The findings are useful and highly topical amid the SARS-CoV-2 pandemic, especially with relation 
to the issue of immunity and re-infection. 
 
I have a few minor comments:
It would be great to see some of the data disaggregated by IMD and also ethnicity (or if not 
individual ethnicity perhaps proportion of BAME people in LSOA from where swab sent) as it 
1. 
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is mentioned that these data are collected. This is highly pertinent to the evidence that is 
gathering about the differential impact of Covid-19 in BAME and amongst people of lower 
socioeconomic status. The issue of under-reporting in these groups is mentioned early in 
the manuscript and should also perhaps be mentioned in the limitations section. 
 
Please can the authors comment/interpret the findings across age groups that are shown in 
Table 2 (lower HCoV PCR+ illness in older age groups compared to 0-4) and how these might 
be applied to help our understanding of SARS-CoV-2 transmission and illness, especially in 
light of potential lifting of lockdown measures including school closures. 
 
2. 
Minor update to Covid-19 global/UK numbers will be required on re-submission of final 
version.
3. 
Congratulations to the authors on an interesting, important, topical, and highly readable piece. 
Thank you for considering me to review.
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Clinical infectious diseases (HIV/TB), epidemiology, social determinants and 
consequences of ill-health.
I confirm that I have read this submission and believe that I have an appropriate level of 
expertise to confirm that it is of an acceptable scientific standard, however I have 
significant reservations, as outlined above.
Author Response 30 Nov 2020
Robert Aldridge, UCL, London, UK 
Thanks very much for this helpful review - we appreciate the time you have taken to 
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carefully read and provide constructive feedback on the article. We have tried to address all 
the points you have raised and below we include your comments alongside in our 
responses in bold italics. We have numbered each of our responses in order that we can 
cross-reference them across all of the reviews to this article.  
 
Reviewer comment 1:  
 
It would be great to see some of the data disaggregated by IMD and also ethnicity (or if not 
individual ethnicity perhaps proportion of BAME people in LSOA from where swab sent) as it 
is mentioned that these data are collected. This is highly pertinent to the evidence that is 
gathering about the differential impact of Covid-19 in BAME and amongst people of lower 
socioeconomic status. The issue of under-reporting in these groups is mentioned early in 
the manuscript and should also perhaps be mentioned in the limitations section. 
 
Author response 1:  
 
Thank you for these suggestions which we have considered carefully. Table 2 provides data 
by IMD, but unfortunately it has not been possible to stratify other results of the study (e.g. 
Figure 1 or Table 3) by ethnicity status or IMD due to low number of events in these groups. 
We have added the following note about this in the discussion: 
 
“Finally, because of small numbers in sub-groups it has not been possible to stratify our 
results socio-economic status or ethnicity despite the fact that they are increasingly 
recognised as important factors associated with COVID-19 outcomes.” 
 
Reviewer comment 2:  
 
Please can the authors comment/interpret the findings across age groups that are shown in 
Table 2 (lower HCoV PCR+ illness in older age groups compared to 0-4) and how these might 
be applied to help our understanding of SARS-CoV-2 transmission and illness, especially in 
light of potential lifting of lockdown measures including school closures. 
 
Author response 2:  
 
Table 2 suggests that compared to the 0-4 age group, all other ages have a lower rate ratio 
of HCoV PCR+ illness. We are very cautious in our interpretation of this suggestion as the 0-
4 age group also had the smallest number of events. In response to this reviewer comment 
we explored the possibility of modelling age as a continuous variable to improve our 
modelling approach. We also explored the possibility of including age with 
polynomials/splines. Unfortunately both of these approaches resulted in models that were 
more difficult to interpret and did not help with interpreting differences in HCoV PCR+ 
illness in older age groups compared to 0-4 as suggested. As a result, we do not think we 
can explore this issue further. However, we have edited the text describing these results as 
set out in response to Reviewer 2 comment 10.  
 
Reviewer comment 3:  
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Minor update to Covid-19 global/UK numbers will be required on re-submission of final 
version. 
 
Author response 3:  
 
We have updated our analyses with the latest Covid-19 global/UK numbers and edited the 
text in the introduction in light of the current situation.  
Competing Interests: No competing interests were disclosed.
Comments on this article
Version 1
Reader Comment 07 May 2020
Oswald Hotz de Baar, None, UK 
Sirs, 
From the outset when the Imperial study was presented the pattern of C19 infection seemed odd. 
Firstly 50% were believed to have had the disease with little or no symptoms and even those who 
were hospitalised generally recovered without recourse to intensive care. Reports from Diamond 
Princess also had an odd pattern with some spouses of infected people apparently never 
succumbed even though exposure must have been high. It looked to me as if a section of the 
population had acquired some immunity from a previous coronavirus infection. I would argue that 
this proposal is supported by what you have presented here. It would be nice to have some 
estimate of the proportion of the population likely to have been previously infected with one of 
these common cold coronaviruses when averaged over decades. I am not sure if you have sampled 
infants and young children although one might assume that resistance may have waned 
significantly after a few decades unless reinfection has occurred. 
If it tiurns out that a significant proportion (say circa 50%) have been infected then there is a prima 
facia case that one or more of the common cold coronaviruses will provide some or good immunity 
and since its already wild registration should be rather easy.
Competing Interests: No competing interests were disclosed.
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